SCHEMBL30058554

SCHEMBL30058554

CC(C)(C)OC(=O)Nc1ccc(-c2ccco2)cc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 4/20 0.49
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRA6 Q16445 1/20 0.44
AAK1 Q2M2I8 5/20 0.44
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
TAAR1 Q96RJ0 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA3 P0DMS8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5868979 1.00 HDAC2 (0.49) HDAC2GABRA1GABRG2GABRB3GABRA5
Ammonia Solution, Strong SCHEMBL21835776 0.99 HDAC2 (0.48) HDAC2GABRA1GABRG2GABRB3GABRA5
SCHEMBL5868773 0.81 NPC1 (0.50) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL1753916 0.81 ABCB1 (0.54) HDAC2AAK1CYP17A1HDAC3
SCHEMBL5868802 0.81 ABCB1 (0.54) HDAC2AAK1CYP17A1HDAC3
SCHEMBL20163156 0.80 HDAC2 (0.60) HDAC2TAAR1HDAC3
Ammonia Solution, Strong SCHEMBL21835798 0.80 ABCB1 (0.53) HDAC2AAK1CYP17A1HDAC3
SCHEMBL3786645 0.79 AAK1 (0.53) HDAC2AAK1NPC1CYP17A1
SCHEMBL5868855 0.79 HDAC2 (0.54) HDAC2AAK1KDM4EMEN1ALDH1A1
SCHEMBL30058274 0.79 HDAC2 (0.47) HDAC2AAK1CYP17A1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-01-03 US disclosed
US-20220281833-A1 SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2022-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 HDAC2 2/4885GABRA1 3434/4885GABRG2 2317/4885
US-20220281833-A1 SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS HDAC1, HDAC2, HDAC11 HDAC2 2/4885GABRA1 3496/4885GABRG2 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.